It is very well documented that the expression of constitutively activated tyrosine kinase, which is a product of BCR-ABL, is the underlying reason for the CML phenotype [2,3]. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.